The U.S. Food and Drug Administration has approved certain nootropics to treat conditions like attention-deficit hyperactivity disorder and narcolepsy. These drugs are commonly misused by students and other individuals looking to boost memory and learning capabilities. This off-label use can incite a number of adverse mental health conditions.
“As temptation grows to use prescription drugs for a competitive advantage at work and school, the nonmedical use of these drugs should be discouraged given potential for substance misuse and other adverse consequences,” said Maya A. Babu, MD, AMA board member. “The AMA believes physicians can support this goal by not prescribing any drug for the purpose of cognitive enhancement in otherwise healthy individuals.”
More articles on physician issues:
AMA inaugurates new president, chooses new president-elect
7 policies adopted at AMA’s annual meeting
Millennial physicians have ‘casual approach’ to social media: What does this mean for patient care, privacy?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
